Laboratory Considerations for Clinical Trials
Science:Life Sciences
In this episode, Dr. Wayne Hogrefe and Dr. Pat Hurban discuss the use of NGS in the development and assessment of new vaccines against the influenza virus.
Topics covered include:
- What health organizations are looking for that drives the selection of the next season's vaccine strains
- How sequence data is used to evaluate the effectiveness of a vaccine while providing insight into the evolution of the virus
- How the sequence data can inform the development of new types of vaccines and therapeutics
- The prospects for a vaccine that is effective across multiple strains and multiple seasons
- How NGS data differs from traditional Sanger sequencing data and what can be learned from that
You can learn more about this topic at www.q2labsolutions.com
More Episodes
Flexible Approaches for Biotech Companies in Clinical Trials
2022-06-22
217
2022-06-22
217
Risk Management for Biotech Companies in Clinical Trials
2022-05-16
172
2022-05-16
172
Managing Sample Data from Vendors
2021-09-14
214
2021-09-14
214
Automation within an ADME Laboratory
2021-08-26
197
2021-08-26
197
Bioanalytical Automation of Samples
2021-07-30
166
2021-07-30
166
Consent Tracking for Clinical Samples
2021-07-28
163
2021-07-28
163
Tracking Clinical Trial Samples
2021-07-28
158
2021-07-28
158
Avoiding Canceled Tests in Pediatric Samples
2021-02-02
139
2021-02-02
139
Covid Vaccine Testing
2020-09-15
185
2020-09-15
185
Hybrid Assays for Protein Bioanalysis
2020-07-29
148
2020-07-29
148
High Throughput ADME Testing
2020-07-29
95
2020-07-29
95
Liquid Biopsy Collection in Clinical Development Programs
2020-07-29
114
2020-07-29
114
Companion Diagnostic Strategies for Commercial Success
2019-02-26
194
2019-02-26
194
Get this podcast on your
phone, FREE
